Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (81-90 of 301) with videos related to

Pageof 31
Sort By:
International Journal of Technology Assessment in Health Care|September 28, 2004
Cross-national comparison of technology assessment processesAnna García-Altés, Silvia Ondategui-Parra, Peter J Neumann
Health Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J Neumann
The New England Journal of Medicine|February 15, 2008
Does preventive care save money? Health economics and the presidential candidatesJoshua T Cohen, Peter J Neumann, Milton C Weinstein
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 13, 2022
The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness AnalysisPeter J Neumann, Louis P Garrison, Richard J Willke
Pediatric Neurology|October 23, 2016
Willingness to Pay for a Newborn Screening Test for Spinal Muscular AtrophyPei-Jung Lin, Wei-Shi Yeh, Peter J Neumann
Annals of Internal Medicine|August 29, 2017
A Call for Open-Source Cost-Effectiveness AnalysisJoshua T Cohen, Peter J Neumann, John B Wong
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
Understanding the medical and nonmedical value of diagnostic testingDavid W Lee, Peter J Neumann, John A Rizzo
Health Affairs (Project Hope)|November 11, 2008
Medicare's national coverage decisions for technologies, 1999-2007Peter J Neumann, Maki S Kamae, Jennifer A Palmer
The American Journal of Managed Care|August 20, 2016
The impact of formulary drug exclusion policies on patients and healthcare costsJames D Chambers, Pallavi B Rane, Peter J Neumann
The New England Journal of Medicine|August 28, 2014
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY thresholdPeter J Neumann, Joshua T Cohen, Milton C Weinstein
Pageof 31

Showing results (81-90 of 301) with videos related to

Sort By:
Pageof 31
International Journal of Technology Assessment in Health Care|September 28, 2004
Cross-national comparison of technology assessment processesAnna García-Altés, Silvia Ondategui-Parra, Peter J Neumann
Health Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J Neumann
The New England Journal of Medicine|February 15, 2008
Does preventive care save money? Health economics and the presidential candidatesJoshua T Cohen, Peter J Neumann, Milton C Weinstein
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 13, 2022
The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness AnalysisPeter J Neumann, Louis P Garrison, Richard J Willke
Pediatric Neurology|October 23, 2016
Willingness to Pay for a Newborn Screening Test for Spinal Muscular AtrophyPei-Jung Lin, Wei-Shi Yeh, Peter J Neumann
Annals of Internal Medicine|August 29, 2017
A Call for Open-Source Cost-Effectiveness AnalysisJoshua T Cohen, Peter J Neumann, John B Wong
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
Understanding the medical and nonmedical value of diagnostic testingDavid W Lee, Peter J Neumann, John A Rizzo
Health Affairs (Project Hope)|November 11, 2008
Medicare's national coverage decisions for technologies, 1999-2007Peter J Neumann, Maki S Kamae, Jennifer A Palmer
The American Journal of Managed Care|August 20, 2016
The impact of formulary drug exclusion policies on patients and healthcare costsJames D Chambers, Pallavi B Rane, Peter J Neumann
The New England Journal of Medicine|August 28, 2014
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY thresholdPeter J Neumann, Joshua T Cohen, Milton C Weinstein
Pageof 31